What are the indications, recommended dosing, contraindications, and monitoring recommendations for montelukast?

Montelukast: Clinical Overview

Montelukast is a leukotriene receptor antagonist (LTRA) approved for asthma and allergic rhinitis, but it is NOT a first-line agent for either condition and carries an FDA black box warning for serious neuropsychiatric adverse events including suicidality.

Indications

Asthma

• Alternative therapy (not preferred) for mild persistent asthma in patients ≥1 year old who cannot or will not use inhaled corticosteroids 1
• Add-on therapy to inhaled corticosteroids for moderate persistent asthma (Step 3), though long-acting beta-agonists are preferred 1
• Not effective as a third medication in severe persistent asthma already on medium-to-high dose inhaled corticosteroids plus long-acting beta-agonists 2

Allergic Rhinitis

• Second-line therapy for seasonal allergic rhinitis in patients ≥15 years old—intranasal corticosteroids are significantly more effective and should be used first 3
• May be considered when patients refuse intranasal corticosteroids or have concurrent mild persistent asthma, though it remains suboptimal for both conditions 3

Dosing

Age-Based Dosing (Once Daily)

• 6-23 months: 4 mg oral granules 4, 5
• 2-5 years: 4 mg chewable tablet 4, 6, 5
• 6-14 years: 5 mg chewable tablet 4, 5, 7
• ≥15 years: 10 mg film-coated tablet 5, 7

Key dosing principles:

• Administer once daily in the evening for asthma 5
• Can be taken with or without food 5
• Continue daily even when asymptomatic 5

Contraindications and Critical Warnings

FDA Black Box Warning (March 2020)

Serious neuropsychiatric events have been reported, including:

• Agitation, aggression, anxiety, depression
• Sleep disturbances, nightmares
• Suicidal thoughts and behavior
• Hallucinations, tremor 8, 9

Action required: Discontinue immediately if any neuropsychiatric symptoms occur 8

Relative Contraindications

• Known hypersensitivity to montelukast
• Acute asthma attacks (not for rescue therapy) 5
• Aspirin-sensitive asthma patients should continue aspirin avoidance 5

Special Populations

• Hepatic impairment (mild-to-moderate): No dose adjustment needed; 41% higher AUC but clinically acceptable 5
• Severe hepatic impairment: Not studied—use with extreme caution 5
• Renal impairment: No dose adjustment needed (not renally excreted) 5
• Pregnancy: Category B—use only if clearly needed 5
• Nursing mothers: Excreted in rat milk; unknown in humans—use with caution 5

Phenylketonuria Warning

Chewable tablets contain phenylalanine:

• 4 mg tablet: 0.674 mg phenylalanine
• 5 mg tablet: 0.842 mg phenylalanine 5

Monitoring Recommendations

Mandatory Monitoring

1. Neuropsychiatric symptoms: Screen at every visit for mood changes, behavioral changes, sleep disturbances, suicidal ideation 8, 9
2. Asthma control: Assess symptom frequency, rescue inhaler use (>2 days/week indicates inadequate control), nighttime awakenings 1
3. Therapeutic response: Evaluate within 4-6 weeks; discontinue if no clear benefit 6

Clinical Monitoring Parameters

• Impairment domain: Daytime symptoms, nighttime awakenings, interference with normal activity, rescue medication use
• Risk domain: Exacerbation frequency, lung function decline, medication adverse effects 10

When to Discontinue

• Any neuropsychiatric adverse event occurs 8
• No clear benefit after 4-6 weeks of therapy 6
• Asthma well-controlled for ≥3 months (attempt step-down) 1
• Patient requires step-up to higher intensity therapy 1

Drug Interactions

Minimal clinically significant interactions:

• No dose adjustment needed with theophylline, warfarin, digoxin, oral contraceptives, or terfenadine 5
• Phenobarbital and rifampin: Decrease montelukast AUC by ~40%; monitor clinical response but no dose adjustment recommended 5
• Does not inhibit CYP2C8, 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 in vivo 5

Key Clinical Pitfalls

1. Never use as monotherapy for acute asthma exacerbations—patients must have short-acting beta-agonist available 5
2. Do not abruptly discontinue other asthma medications when starting montelukast 5
3. Not a substitute for inhaled corticosteroids in moderate-to-severe asthma—inferior efficacy for symptom control 3, 11
4. Delayed onset of action (within 1 hour but maximal effect takes days)—not suitable for immediate symptom relief 12
5. High variability in young infants (6-11 months): 60% higher AUC and 89% higher Cmax than adults, though generally well-tolerated 5

Comparative Efficacy

Intranasal corticosteroids are clinically and statistically superior to montelukast for allergic rhinitis with meaningful reductions in nasal symptoms 3. Inhaled corticosteroids are superior to montelukast for asthma, particularly for nighttime symptom control 11. Montelukast offers convenience (once-daily oral dosing) and high compliance but at the cost of reduced efficacy and significant neuropsychiatric risk 1, 12.